140 related articles for article (PubMed ID: 36807226)
1. Coupling between GPR143 and dopamine D2 receptor is required for selective potentiation of dopamine D2 receptor function by L-3,4-dihydroxyphenylalanine in the dorsal striatum.
Masukawa D; Kitamura S; Tajika R; Uchimura H; Arai M; Takada Y; Arisawa T; Otaki M; Kanai K; Kobayashi K; Miyazaki T; Goshima Y
J Neurochem; 2023 Apr; 165(2):177-195. PubMed ID: 36807226
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of Haloperidol-Induced Catalepsy by GPR143, an L-Dopa Receptor, in Striatal Cholinergic Interneurons.
Arai M; Suzuki E; Kitamura S; Otaki M; Kanai K; Yamasaki M; Watanabe M; Kambe Y; Murata K; Takada Y; Arisawa T; Kobayashi K; Tajika R; Miyazaki T; Yamaguchi M; Lazarus M; Hayashi Y; Itohara S; de Kerchove d'Exaerde A; Nawa H; Kim R; Bito H; Momiyama T; Masukawa D; Goshima Y
J Neurosci; 2024 Mar; 44(11):. PubMed ID: 38286627
[TBL] [Abstract][Full Text] [Related]
3. L-DOPA-Induced Neurogenesis in the Hippocampus Is Mediated Through GPR143, a Distinct Mechanism of Dopamine.
Kasahara Y; Masukawa D; Kobayashi K; Yamasaki M; Watanabe M; Goshima Y
Stem Cells; 2022 Mar; 40(2):215-226. PubMed ID: 35257172
[TBL] [Abstract][Full Text] [Related]
4. D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease.
Paul ML; Graybiel AM; David JC; Robertson HA
J Neurosci; 1992 Oct; 12(10):3729-42. PubMed ID: 1357113
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of the gene product of ocular albinism 1 (GPR143/OA1) but not its mutant forms inhibits neurite outgrowth in PC12 cells.
Masukawa D; Yamada K; Goshima Y
J Pharmacol Sci; 2019 Sep; 141(1):41-48. PubMed ID: 31606330
[TBL] [Abstract][Full Text] [Related]
6. Immunoreactivity of a G protein-coupled l-DOPA receptor GPR143, in Lewy bodies.
Goshima Y; Watanabe S; Seki E; Koga M; Masukawa D; Nakamura F; Komori T; Arai N
Neurosci Res; 2019 Nov; 148():49-53. PubMed ID: 30590075
[TBL] [Abstract][Full Text] [Related]
7. Increased sensitivity in the interaction of the dopaminergic/adenosinergic system at the level of the adenylate cyclase activity in the striatum of the "weaver" mouse.
K B; V T; N P; M M; N M; F A
Neurochem Int; 2016 Oct; 99():233-238. PubMed ID: 27498335
[TBL] [Abstract][Full Text] [Related]
8. l-3,4-Dihydroxyphenylalanine induces ptosis through a GPR143-independent mechanism in mice.
Ueda S; Masukawa D; Koga M; Goshima Y
J Pharmacol Sci; 2016 Sep; 132(1):109-112. PubMed ID: 27622543
[TBL] [Abstract][Full Text] [Related]
9. l-DOPA promotes striatal dopamine release through D1 receptors and reversal of dopamine transporter.
Viaro R; Longo F; Vincenzi F; Varani K; Morari M
Brain Res; 2021 Oct; 1768():147583. PubMed ID: 34284020
[TBL] [Abstract][Full Text] [Related]
10. Reduced striatal dopamine DA D2 receptor function in dominant-negative GSK-3 transgenic mice.
Gomez-Sintes R; Bortolozzi A; Artigas F; Lucas JJ
Eur Neuropsychopharmacol; 2014 Sep; 24(9):1524-33. PubMed ID: 25088904
[TBL] [Abstract][Full Text] [Related]
11. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Hossain MA; Weiner N
J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
[TBL] [Abstract][Full Text] [Related]
12. L-DOPA Oppositely Regulates Synaptic Strength and Spine Morphology in D1 and D2 Striatal Projection Neurons in Dyskinesia.
Suarez LM; Solis O; Aguado C; Lujan R; Moratalla R
Cereb Cortex; 2016 Oct; 26(11):4253-4264. PubMed ID: 27613437
[TBL] [Abstract][Full Text] [Related]
13. Involvement of the L-DOPA receptor GPR143 in acute and chronic actions of methylphenidate.
Uchimura H; Kanai K; Arai M; Inoue M; Hishimoto A; Masukawa D; Goshima Y
J Pharmacol Sci; 2023 Jul; 152(3):178-181. PubMed ID: 37257945
[TBL] [Abstract][Full Text] [Related]
14. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
Hu XT; White FJ
Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
[TBL] [Abstract][Full Text] [Related]
15. Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease.
Wakamatsu M; Iwata S; Funakoshi T; Yoshimoto M
J Neurosci Res; 2008 Feb; 86(3):640-6. PubMed ID: 17896793
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
[TBL] [Abstract][Full Text] [Related]
17. Dopamine D2 receptor overexpression alters behavior and physiology in Drd2-EGFP mice.
Kramer PF; Christensen CH; Hazelwood LA; Dobi A; Bock R; Sibley DR; Mateo Y; Alvarez VA
J Neurosci; 2011 Jan; 31(1):126-32. PubMed ID: 21209197
[TBL] [Abstract][Full Text] [Related]
18. Rotation and striatal c-fos expression after repeated, daily treatment with selective dopamine receptor agonists and levodopa.
Asin KE; Bednarz L; Nikkel A; Perner R
J Pharmacol Exp Ther; 1995 Jun; 273(3):1483-90. PubMed ID: 7791123
[TBL] [Abstract][Full Text] [Related]
19. Levodopa biotransformation in hemi-Parkinson rats: effect of dopamine receptor agonists and antagonists.
Sarre S; Ebinger G; Michotte Y
Eur J Pharmacol; 1996 Feb; 296(3):247-60. PubMed ID: 8904076
[TBL] [Abstract][Full Text] [Related]
20. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
Wachtel SR; Hu XT; Galloway MP; White FJ
Synapse; 1989; 4(4):327-46. PubMed ID: 2532422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
